Similar articles for PMID: 27083210

Year	Number of Results
1996	1
2002	1
2003	1
2005	1
2006	1
2007	2
2008	1
2009	2
2010	2
2011	1
2012	3
2013	2
2014	7
2015	8
2016	7
2017	11
2018	4
2019	6
2020	11
2021	19
2022	15
2023	14
2024	3

1

Persistence of immunophenotypically aberrant CD34+ myeloid progenitors is frequent in bone marrow of patients with myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms treated with hypomethylating agents.

Huang L, Garcia-Manero G, Jabbour E, Goswami M, Routbort MJ, Medeiros LJ, Jorgensen JL, Wang SA. Huang L, et al. J Clin Pathol. 2016 Apr 15:jclinpath-2016-203715. doi: 10.1136/jclinpath-2016-203715. Online ahead of print. J Clin Pathol. 2016. PMID: 27083210

2

Flow cytometry immunophenotypic analysis of Philadelphia-negative myeloproliferative neoplasms: Correlation with histopathologic features.

Ouyang J, Zheng W, Shen Q, Goswami M, Jorgensen JL, Medeiros LJ, Wang SA. Ouyang J, et al. Cytometry B Clin Cytom. 2015 Jul-Aug;88(4):236-43. doi: 10.1002/cyto.b.21215. Epub 2014 Dec 30. Cytometry B Clin Cytom. 2015. PMID: 25557358 Free article.

3

Flow cytometry immunophenotypic analysis of Philadelphia-negative myeloproliferative neoplasms: Correlation with histopathologic features.

Ouyang J, Zheng W, Shen Q, Goswami M, Jorgensen JL, Medeiros LJ, Wang SA. Ouyang J, et al. Cytometry B Clin Cytom. 2014 Dec 11. doi: 10.1002/cytob.21215. Online ahead of print. Cytometry B Clin Cytom. 2014. PMID: 25504846 Free article.

4

Flow cytometry immunophenotypic findings in chronic myelomonocytic leukemia and its utility in monitoring treatment response.

Shen Q, Ouyang J, Tang G, Jabbour EJ, Garcia-Manero G, Routbort M, Konoplev S, Bueso-Ramos C, Medeiros LJ, Jorgensen JL, Wang SA. Shen Q, et al. Eur J Haematol. 2015 Aug;95(2):168-76. doi: 10.1111/ejh.12477. Epub 2015 Apr 17. Eur J Haematol. 2015. PMID: 25354960

5

A Pilot Clinical Study to Investigate the Hypomethylating Properties of Freeze-dried Black Raspberries in Patients with Myelodysplastic Syndrome or Myeloproliferative Neoplasm.

Dong A, Pan X, Lin CW, Huang YW, Krause H, Pan P, Baim A, Thomas MJ, Chen X, Yu J, Michaelis L, Liu P, Wang LS, Atallah E. Dong A, et al. J Cancer Prev. 2022 Jun 30;27(2):129-138. doi: 10.15430/JCP.2022.27.2.129. J Cancer Prev. 2022. PMID: 35864858 Free PMC article.

6

Deep immunophenotypic analysis of the bone marrow progenitor cells in myelodysplastic syndromes.

Shameli A, Dharmani-Khan P, Auer I, Shabani-Rad MT. Shameli A, et al. Leuk Res. 2023 Nov;134:107401. doi: 10.1016/j.leukres.2023.107401. Epub 2023 Sep 23. Leuk Res. 2023. PMID: 37774446

7

Real-world use and outcomes of hypomethylating agent therapy in higher-risk myelodysplastic syndromes: why are we not achieving the promise of clinical trials?

Zeidan AM, Salimi T, Epstein RS. Zeidan AM, et al. Future Oncol. 2021 Dec;17(36):5163-5175. doi: 10.2217/fon-2021-0936. Epub 2021 Oct 12. Future Oncol. 2021. PMID: 34636250 Free article. Review.

8

Exploring blast composition in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms: CD45RA and CD371 improve diagnostic value of flow cytometry through assessment of myeloblast heterogeneity and stem cell aberrancy.

Shameli A, Dharmani-Khan P, Luider J, Auer I, Shabani-Rad MT. Shameli A, et al. Cytometry B Clin Cytom. 2021 Sep;100(5):574-589. doi: 10.1002/cyto.b.21983. Epub 2020 Dec 24. Cytometry B Clin Cytom. 2021. PMID: 33369070 Free PMC article.

9

Dynamics of PD-1 expression are associated with treatment efficacy and prognosis in patients with intermediate/high-risk myelodysplastic syndromes under hypomethylating treatment.

Geng S, Xu R, Huang X, Li M, Deng C, Lai P, Wang Y, Wu P, Chen X, Weng J, Du X. Geng S, et al. Front Immunol. 2022 Aug 8;13:950134. doi: 10.3389/fimmu.2022.950134. eCollection 2022. Front Immunol. 2022. PMID: 36003379 Free PMC article.

10

Acute leukemia arising from myeloproliferative or myelodysplastic/myeloproliferative neoplasms: A series of 372 patients from the PETHEMA AML registry.

Hernández-Boluda JC, Martínez-Cuadrón D, Pereira A, Rodríguez-Veiga R, Boluda B, Gil C, Casal-Marini S, Serrano J, Martínez-López J, Bergua J, Algarra L, Bernal T, López-Lorenzo JL, Colorado M, López A, Tormo M, Sayas MJ, Trigo F, López-Pavía M, Pérez-Simón JA, Lavilla-Rubira E, Rodríguez-Medina C, Rodríguez-Gutiérrez JI, Sanz-Caballer MA, Montesinos P; PETHEMA group. Hernández-Boluda JC, et al. Leuk Res. 2022 Apr;115:106821. doi: 10.1016/j.leukres.2022.106821. Epub 2022 Mar 6. Leuk Res. 2022. PMID: 35286939

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

101 results

Results by year